Clinical Trial

Oncolytic Virus in Esophageal Squamous Cell Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). The primary endpoints are safety, surgical conversion rate and event-free survival (EFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), and quality of life (QoL). Exploratory endpoints include biomarker analyses such as single-cell sequencing.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-08; most recent amendment 2025-12-01.
Trial Details
NCT Number NCT07061704
Lead Sponsor Sichuan University
Conditions Esophageal Cancer
Enrollment 40 participants
Start Date 2025-08-01
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-08